Agreement creates a full suite of discovery, development and testing services to support antibiotic and vaccine development projects
ALBANY, N.Y., May 19, 2016 -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that it has entered into a collaboration agreement with CUBRC, Inc. (“CUBRC”), deepening the offerings that both companies provide to their customers. AMRI brings to the collaboration fully integrated drug discovery, high-throughput and high-content screening and medicinal chemistry capabilities, as well as API and product manufacturing services to support CUBRC’s customers. CUBRC brings deep scientific and systems integration expertise and specialized laboratory facilities for biodefense pathogens and multi-drug resistant organisms.
CUBRC’s Biological and Medical Sciences Group serves the National Institutes of Health, the National Institute of Allergy and Infectious Disease, the Biological Advanced Research and Development Authority and the Department of Defense on projects aimed at developing treatments for use against public health indications as well as for those associated with naturally emerging and manmade biological threats.
“CUBRC offers specialized capabilities for working with highly pathogenic and sensitive materials for biodefense projects and operates biosafety level 3 facilities to allow for the safe conduct of R&D with these pathogens,” said Rory Curtis, Ph.D., Vice President, Discovery Biology and Pharmacology, and Site Head of AMRI’s new fully integrated drug discovery facility in Buffalo. “CUBRC’s capabilities extend our established expertise in the area of antibacterial drug discovery. Together with our expertise in assay development, medicinal chemistry and protein production, we can offer customers access to a full spectrum of discovery and development services.”
“AMRI’s integrated drug discovery center located at the Buffalo Niagara Medical Campus is a premier facility for subcontracting our discovery and medicinal chemistry work, and our clients will appreciate the other world-class facilities and customer service for development and manufacturing work,” said David Mangino, Vice President of CUBRC’s Chemical, Biological and Medical Sciences Sector. “With this agreement, CUBRC can access AMRI’s capabilities right here in Western New York to broaden our offerings to our clients and enhance our ability to pursue large government-funded advanced R&D programs requiring a very deep base of drug discovery and developmental research experience and capabilities.”
About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
About CUBRC
CUBRC, Inc. is an independent, not-for-profit, scientific company headquartered in Buffalo, NY, which performs research, development, testing and systems integration in the fields of high-speed aeronautics, command and control, data sciences and information fusion, and chemical, biological and medical sciences. CUBRC offers a world-class scientific team having expertise in drug development and proven experience with Federal procurement processes to serve as a systems integrator for medical countermeasure development programs. CUBRC leads a team of partners comprising early and mid-stage pharmaceutical companies developing treatments, to include antimicrobial drugs and vaccines that address important unmet medical needs associated with public health and biological threats. To learn more about CUBRC, please visit www.cubrc.org.
ALBANY, N.Y., May 19, 2016 -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that it has entered into a collaboration agreement with CUBRC, Inc. (“CUBRC”), deepening the offerings that both companies provide to their customers. AMRI brings to the collaboration fully integrated drug discovery, high-throughput and high-content screening and medicinal chemistry capabilities, as well as API and product manufacturing services to support CUBRC’s customers. CUBRC brings deep scientific and systems integration expertise and specialized laboratory facilities for biodefense pathogens and multi-drug resistant organisms.
CUBRC’s Biological and Medical Sciences Group serves the National Institutes of Health, the National Institute of Allergy and Infectious Disease, the Biological Advanced Research and Development Authority and the Department of Defense on projects aimed at developing treatments for use against public health indications as well as for those associated with naturally emerging and manmade biological threats.
“CUBRC offers specialized capabilities for working with highly pathogenic and sensitive materials for biodefense projects and operates biosafety level 3 facilities to allow for the safe conduct of R&D with these pathogens,” said Rory Curtis, Ph.D., Vice President, Discovery Biology and Pharmacology, and Site Head of AMRI’s new fully integrated drug discovery facility in Buffalo. “CUBRC’s capabilities extend our established expertise in the area of antibacterial drug discovery. Together with our expertise in assay development, medicinal chemistry and protein production, we can offer customers access to a full spectrum of discovery and development services.”
“AMRI’s integrated drug discovery center located at the Buffalo Niagara Medical Campus is a premier facility for subcontracting our discovery and medicinal chemistry work, and our clients will appreciate the other world-class facilities and customer service for development and manufacturing work,” said David Mangino, Vice President of CUBRC’s Chemical, Biological and Medical Sciences Sector. “With this agreement, CUBRC can access AMRI’s capabilities right here in Western New York to broaden our offerings to our clients and enhance our ability to pursue large government-funded advanced R&D programs requiring a very deep base of drug discovery and developmental research experience and capabilities.”
About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
About CUBRC
CUBRC, Inc. is an independent, not-for-profit, scientific company headquartered in Buffalo, NY, which performs research, development, testing and systems integration in the fields of high-speed aeronautics, command and control, data sciences and information fusion, and chemical, biological and medical sciences. CUBRC offers a world-class scientific team having expertise in drug development and proven experience with Federal procurement processes to serve as a systems integrator for medical countermeasure development programs. CUBRC leads a team of partners comprising early and mid-stage pharmaceutical companies developing treatments, to include antimicrobial drugs and vaccines that address important unmet medical needs associated with public health and biological threats. To learn more about CUBRC, please visit www.cubrc.org.
